Lawn S D, Shattock R J, Acheampong J W, Lal R B, Folks T M, Griffin G E, Butera S T
HIV and Retrovirology Branch, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia 30333, USA.
AIDS. 1999 Nov 12;13(16):2231-7. doi: 10.1097/00002030-199911120-00005.
To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation.
Clinical and microbiological responses, immune activation parameters and plasma HIV-1 load were determined in 20 patients with pulmonary tuberculosis and HIV-1 coinfection in Ghana, West Africa during the first 3 months of anti-tuberculosis treatment.
Plasma HIV-1 load and markers of immune activation were determined by commercially available assays. Human leukocyte antigen (HLA)-DR incorporation into the HIV-1 envelope was measured by using an immunomagnetic capture technique.
Treatment of tuberculosis resulted in significant improvements in weight and haemoglobin, a high sputum smear conversion rate and marked reductions in mean plasma tumour necrosis factor (TNF) receptor-1, interleukin-6 and C-reactive protein. Furthermore, incorporation of host HLA-DR into the HIV-1 envelope decreased; this also suggested a reduction in immune activation of the cells supporting viral replication. However, of importance with regard to AIDS pathogenesis, neither mean plasma TNF-alpha nor HIV-1 load decreased significantly.
The failure of HIV-1 plasma load to decline significantly during the initial months of anti-tuberculosis treatment is associated with high, sustained systemic levels of TNF-alpha. The dissociation between the sustained levels of plasma TNF-alpha and the major reductions in other, diverse immune activation parameters may represent dysregulation of cytokine production in these African patients.
确定结核病治疗对非洲受试者血浆中HIV-1载量的影响,并将病毒载量与治疗反应及免疫激活变化相关联。
在西非加纳20例肺结核合并HIV-1感染患者接受抗结核治疗的前3个月,测定其临床和微生物学反应、免疫激活参数及血浆HIV-1载量。
采用市售检测方法测定血浆HIV-1载量和免疫激活标志物。使用免疫磁捕获技术测量人类白细胞抗原(HLA)-DR掺入HIV-1包膜的情况。
结核病治疗使体重和血红蛋白显著改善,痰涂片转阴率高,血浆肿瘤坏死因子(TNF)-1、白细胞介素-6和C反应蛋白的平均水平显著降低。此外,宿主HLA-DR掺入HIV-1包膜减少;这也表明支持病毒复制的细胞免疫激活降低。然而,就艾滋病发病机制而言,血浆TNF-α平均水平和HIV-1载量均未显著下降。
抗结核治疗最初几个月期间HIV-1血浆载量未能显著下降与TNF-α持续高水平的全身状态有关。血浆TNF-α持续水平与其他多种免疫激活参数大幅降低之间的分离可能代表这些非洲患者细胞因子产生失调。